The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.
An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible
INCLUSION Global Study Details
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries. For more details on all ongoing LEN implementation studies, see our map and visit the integrated study dashboard.
Long-Acting PrEP Generic License Coverage
This map shows country coverage under current voluntary licensing agreements for generic versions of three long-acting PrEP products: alimatravir (AMI), cabotegravir (CAB) and lenacapavir (LEN). The graphic reflects publicly announced licenses and does not indicate product registration, availability or access within countries. For more information, visit the PrEPWatch Long-Acting PrEP Status page.
Lenacapavir Implementation Studies
Ongoing and planned implementation studies for the lenacapavir as of July 2026. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Injectable PrEP Regulatory Approvals
This graphic tracks regulatory approvals for injectable Cabotegravir and Lenacapavir for PrEP as of July 2026. For additional details on product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Potential Lenacapavir Supply, 2026-28
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
HIV Cure Research Cohorts
HIV cure research depends on cohorts of people living with HIV who volunteer to participate in studies over many years. These cohorts help researchers understand how HIV persists in the body, identify factors that may influence the success of cure strategies and evaluate promising interventions. This infographic highlights major HIV cure research cohorts around the world, demonstrating the global collaboration and long-term investment required to advance HIV cure science.
Source of Lenacapavir for PrEP Supply to Early Adopter Countries
The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.
HIV Vaccine Clinical Trials Pipeline
This graphic summarizes the state of HIV vaccine research, detailing the different immunological approaches in clinical trials, the specific candidates being studied, and the collaborative networks of funders and developers working toward an effective vaccine.
HIV Prevention Product Overview
The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.